Sandborn William J.'s Form 4 filing
Ventyx Biosciences, Inc. (VTYX) · filed Dec 16, 2022
- Accession no.
- 0000899243-22-038836
- Filed
- Dec 16, 2022, 5:00 PM ET
- Trade date
- Dec 14, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $1.45M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandborn William J.CIK 0001923805 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | Common Stock | MOption exerciseAcquired | +2,391 | $3.54 | +$8,464.14 | 50,780 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseAcquired | +3,189 | $1.73 | +$5,516.97 | 53,969 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseAcquired | +16,180 | $0.20 | +$3,236 | 70,149 | Direct | |
| Dec 14, 2022 | Common Stock | SSaleDisposed | −21,760 | $33.87F1 | −$737,085.18 | 48,389 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseAcquired | +20,922 | $0.20 | +$4,184.4 | 55,799 | Indirect | |
| Dec 14, 2022 | Common Stock | SSaleDisposed | −20,922 | $33.87F2 | −$708,632.32 | 34,877 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | Common Stock | MOption exerciseDisposed | −2,391 | $0.00 | $0 | 0 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseDisposed | −3,189 | $0.00 | $0 | 0 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseDisposed | −16,180 | $0.00 | $0 | 32,209 | Direct | |
| Dec 14, 2022 | Common Stock | MOption exerciseDisposed | −20,922 | $0.00 | $0 | 3,272 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average share price of an aggregate total of 21,760 shares sold in the price range of $33.5325 to $34.10. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the weighted average share price of an aggregate total of 20,922 shares sold in the price range of $33.5325 to $34.10. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Medical Officer